This site is intended for healthcare professionals
Drug information


Read time: 22 mins
Last updated: 06 May 2020
Published: 01 Apr 2021

4.1 Therapeutic indications

Levofloxacin 500mg Film-coated Tablets is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):

• Acute bacterial sinusitis

• Uncomplicated cystitis (see section 4.4)

• Acute exacerbation of chronic obstructive pulmonary disease including bronchitis

• Complicated skin and soft tissue infections/complicated skin and skin structure infections

For the above-mentioned infections Levofloxacin 500mg Film-coated Tablets should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.

• Acute pyelonephritis and complicated urinary tract infections (see section 4.4)

• Chronic bacterial prostatitis

• Community-acquired pneumonia

• Inhalation Anthrax: post exposure prophylaxis and curative treatment (see section 4.4)

Levofloxacin 500mg Film-coated Tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).